论文部分内容阅读
目的：探讨氨磺必利治疗以阴性症状为主的精神分裂症患者的临床疗效和安全性。方法将85例以阴性症状为主的精神分裂症患者随机分为两组，研究组口服氨磺必利治疗，对照组口服奥氮平治疗，观察12周。采用简明精神病评定量表和阴性症状评定量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组简明精神病评定量表总分、阴性症状量表总分及各因子分均较治疗前显著下降（ P＜0.01）。研究组总有效率为66.7％，对照组为67.4％，两组比较差异无显著性（ P＞0.05）。两组不良反应较轻微，但研究组失眠发生率显著高于对照组（P＜0.05），嗜睡、便秘、体质量增加发生率显著低于对照组（P＜0.05或0.01）。结论氨磺必利治疗以阴性症状为主的精神分裂症疗效显著且与奥氮平相当，安全性高，对体质量影响较小，有利于提高患者的治疗依从性。“,”Objective T o investigate the efficacy and safety of amisulpride in schizophrenia characterized by negative symptoms (NS) .Methods Eighty‐five NS schizophrenics were randomly assigned to two groups ,research group took orally amisulpride and control group did olanzapine for 12 weeks .Efficacies were assessed with the Brief Psychiatric Rating Scale (BPRS) and Scale for the Assessment of Negative Symptoms (SANS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the BPRS total ,SANS total and each factor score of both groups lowered more significant‐ly compared with pretreatment (P0.05) .Adverse reactions of both groups were mild ,the incidence of insomnia was significantly higher (P<0.05) and that of hyper‐somnia ,constipation and weight gain lower (P<0.05 or 0.01) in research than control group .Conclusion Amisulpride has an evident effect equivalent to olanzapine in the treatment of NS schizophrenia ,higher safety and less influence on body mass and is favorable to the improvement of patients ’ compliance .